FDA nod to Koselugo for adults with Rare NF1 tumors, expanding life-changing treatment

Cardiol Therapeutics wins US patent protection for heart-disease drug platform

The patent will lock in broad protection for the company’s lead therapy CardiolRx and its novel subcutaneous candidate CRD-38

Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases

Roche’s Giredestrant sets new benchmark in early breast cancer treatment

The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival

Merus and Halozyme collaborate to advance subcutaneous Petosemtamab development

Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab

New England Biolabs unveils high-speed flu sequencing tool to bolster global outbreak surveillance

Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing

Briefs: Zydus, Divi's Laboratories and Relonchem

FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

Cenmed and Curavit team up to revolutionize clinical trial logistics

This collaboration turns kitting into a strategic advantage for sponsors and sites

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies